# A TQT Study of Effect of M2951 on Cardiac Repolarization

> **NCT07214935** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Placebo matched to M2951
- **DRUG:** Moxifloxacin
- **DRUG:** M2951 Low Dose
- **DRUG:** M2951 High Dose

## Key facts

- **NCT ID:** NCT07214935
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-08
- **Primary completion:** 2023-08-25
- **Final completion:** 2023-08-25
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07214935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07214935, "A TQT Study of Effect of M2951 on Cardiac Repolarization". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07214935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*